CN1034132A - 含哌啶基环戊基庚烯酸衍生物的水溶液配方 - Google Patents

含哌啶基环戊基庚烯酸衍生物的水溶液配方 Download PDF

Info

Publication number: CN1034132A
Authority: CN; China
Prior art keywords: compd; solution; hydrochlorate; cyclodextrin; water
Prior art date: 1987-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN88108916A

Other languages

English (en)

Chinese (zh)

Inventor

哈里·芬奇

安东尼·约翰·菲利普斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-22

Filing date

1988-12-21

Publication date

1989-07-26

1987-12-22 Priority claimed from GB878729823A external-priority patent/GB8729823D0/en

1988-02-25 Priority claimed from GB888804422A external-priority patent/GB8804422D0/en

1988-12-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1989-07-26 Publication of CN1034132A publication Critical patent/CN1034132A/zh

Status Pending legal-status Critical Current

Links

239000013011 aqueous formulation Substances 0.000 title abstract description 5
RWNJOXUVHRXHSD-UHFFFAOYSA-N hept-6-enoic acid Chemical class OC(=O)CCCCC=C RWNJOXUVHRXHSD-UHFFFAOYSA-N 0.000 title description 2
125000005936 piperidyl group Chemical group 0.000 title description 2
239000000243 solution Substances 0.000 claims abstract description 87
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 53
238000002360 preparation method Methods 0.000 claims abstract description 33
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 12
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract description 10
229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract description 10
235000010290 biphenyl Nutrition 0.000 claims abstract description 6
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims abstract description 6
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 40
238000000034 method Methods 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 6
230000001954 sterilising effect Effects 0.000 claims description 6
238000004659 sterilization and disinfection Methods 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 4
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
229960004853 betadex Drugs 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
BCAARMUWIRURQS-UHFFFAOYSA-N dicalcium;oxocalcium;silicate Chemical compound [Ca+2].[Ca+2].[Ca]=O.[O-][Si]([O-])([O-])[O-] BCAARMUWIRURQS-UHFFFAOYSA-N 0.000 claims description 2
238000002347 injection Methods 0.000 abstract description 10
239000007924 injection Substances 0.000 abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
201000010099 disease Diseases 0.000 abstract description 6
239000006188 syrup Substances 0.000 abstract description 3
235000020357 syrup Nutrition 0.000 abstract description 3
239000002775 capsule Substances 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract description 2
150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
230000023555 blood coagulation Effects 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
239000008215 water for injection Substances 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
239000003513 alkali Substances 0.000 description 11
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
229930195725 Mannitol Natural products 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000000594 mannitol Substances 0.000 description 9
235000010355 mannitol Nutrition 0.000 description 9
JIJSGQYJSRWCLG-UHFFFAOYSA-L disodium;2-[hydroxy(2-sulfonatoethyl)amino]ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCN(O)CCS([O-])(=O)=O JIJSGQYJSRWCLG-UHFFFAOYSA-L 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
238000010253 intravenous injection Methods 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000001802 infusion Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000003708 ampul Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
-1 hydroxypropyl Chemical class 0.000 description 4
238000007789 sealing Methods 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000008366 buffered solution Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
235000019980 sodium acid phosphate Nutrition 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000008469 Peptic Ulcer Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical class [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
KFXPOIKSDYRVKS-UHFFFAOYSA-N (Z)-4-Heptenoic acid Natural products CCC=CCCC(O)=O KFXPOIKSDYRVKS-UHFFFAOYSA-N 0.000 description 1
KFXPOIKSDYRVKS-ONEGZZNKSA-N 4-Heptenoic acid Chemical compound CC\C=C\CCC(O)=O KFXPOIKSDYRVKS-ONEGZZNKSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
208000006193 Pulmonary infarction Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000002676 cerebral atherosclerosis Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical class NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
CJCPHVRHJKYIJC-UHFFFAOYSA-N methyl 2-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=CC=C1O CJCPHVRHJKYIJC-UHFFFAOYSA-N 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000007575 pulmonary infarction Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

CN88108916A 1987-12-22 1988-12-21 含哌啶基环戊基庚烯酸衍生物的水溶液配方 Pending CN1034132A (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8729823		1987-12-22
GB878729823A GB8729823D0 (en)	1987-12-22	1987-12-22	Complexes
GB888804422A GB8804422D0 (en)	1988-02-25	1988-02-25	Complexes
GB8804422		1988-02-25

Publications (1)

Publication Number	Publication Date
CN1034132A true CN1034132A (zh)	1989-07-26

Family

ID=26293226

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN88108916A Pending CN1034132A (zh)	1987-12-22	1988-12-21	含哌啶基环戊基庚烯酸衍生物的水溶液配方

Country Status (29)

Country	Link
JP (1)	JPH02210A (sv)
KR (1)	KR890009402A (sv)
CN (1)	CN1034132A (sv)
AT (1)	AT395943B (sv)
AU (1)	AU615245B2 (sv)
BE (1)	BE1001704A3 (sv)
CA (1)	CA1328078C (sv)
CH (1)	CH676665A5 (sv)
DE (1)	DE3843059A1 (sv)
DK (1)	DK712888A (sv)
ES (1)	ES2011727A6 (sv)
FI (1)	FI885920A (sv)
FR (1)	FR2624731B1 (sv)
GB (1)	GB2211737B (sv)
GR (1)	GR880100854A (sv)
HU (1)	HU204700B (sv)
IE (1)	IE61995B1 (sv)
IL (1)	IL88764A0 (sv)
IT (1)	IT1224835B (sv)
LU (1)	LU87411A1 (sv)
MY (1)	MY103952A (sv)
NL (1)	NL8803126A (sv)
NO (1)	NO885689L (sv)
NZ (1)	NZ227446A (sv)
PH (1)	PH24982A (sv)
PL (1)	PL276595A1 (sv)
PT (1)	PT89301B (sv)
SE (1)	SE502288C2 (sv)
ZW (1)	ZW18088A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814725D0 (en) *	1988-06-21	1988-07-27	Glaxo Group Ltd	Medicaments
AU616571B2 (en) *	1988-10-28	1991-10-31	Shiseido Company Ltd.	Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
IT1269578B (it) *	1994-04-22	1997-04-08	Chiesi Farma Spa	Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
KR100825736B1 (ko) *	2005-12-07	2008-04-29	한국전자통신연구원	무선 ｘｍｌ 전자 서명 서비스 제공 장치 및 그 방법
KR100832740B1 (ko) *	2007-01-17	2008-05-27	한국과학기술원	분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS503362B1 (sv) *	1970-06-10	1975-02-04
JPS5443569B2 (sv) *	1972-07-05	1979-12-20
HU181703B (en) *	1980-05-09	1983-11-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS57183772A (en) *	1981-04-29	1982-11-12	Glaxo Group Ltd	Aminocyclopentanol acids and esters, manufacture and medicinal composition
JPS58116423A (ja) *	1981-12-28	1983-07-11	Sumitomo Chem Co Ltd	メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) *	1982-04-30	1983-11-10	Dainippon Pharmaceut Co Ltd	脳神経細胞の酸素欠乏性疾患の治療剤
JPS5946228A (ja) *	1982-09-08	1984-03-15	Zeria Shinyaku Kogyo Kk	生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
JPS5973576A (ja) *	1982-09-16	1984-04-25	グラクソ・グル−プ・リミテツド	ピペリジニルシクロペンタノ−ルヘプテン酸塩
GB2127406B (en) *	1982-09-16	1986-03-05	Glaxo Group Ltd	Piperidinlycyclopentanolheptenoic acid salt
DE3346123A1 (de) *	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60150039A (ja) *	1984-01-17	1985-08-07	Minolta Camera Co Ltd	水陸両用固定焦点カメラ
DE3504044A1 (de) *	1985-02-04	1986-08-07	Schering AG, Berlin und Bergkamen, 1000 Berlin	9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
JPS6327440A (ja) *	1986-07-18	1988-02-05	Sanraku Inc	グルコシル化分岐シクロデキストリン含有組成物

1988
- 1988-12-21 HU HU886537A patent/HU204700B/hu not_active IP Right Cessation
- 1988-12-21 LU LU87411A patent/LU87411A1/fr unknown
- 1988-12-21 JP JP63320759A patent/JPH02210A/ja active Pending
- 1988-12-21 DK DK712888A patent/DK712888A/da not_active Application Discontinuation
- 1988-12-21 AU AU27356/88A patent/AU615245B2/en not_active Ceased
- 1988-12-21 BE BE8801423A patent/BE1001704A3/fr not_active IP Right Cessation
- 1988-12-21 AT AT0313088A patent/AT395943B/de not_active IP Right Cessation
- 1988-12-21 ZW ZW180/88A patent/ZW18088A1/xx unknown
- 1988-12-21 DE DE3843059A patent/DE3843059A1/de not_active Ceased
- 1988-12-21 FI FI885920A patent/FI885920A/fi not_active Application Discontinuation
- 1988-12-21 PT PT89301A patent/PT89301B/pt not_active IP Right Cessation
- 1988-12-21 PH PH37963A patent/PH24982A/en unknown
- 1988-12-21 GB GB8829793A patent/GB2211737B/en not_active Expired - Fee Related
- 1988-12-21 GR GR880100854A patent/GR880100854A/el unknown
- 1988-12-21 CH CH4758/88A patent/CH676665A5/de not_active IP Right Cessation
- 1988-12-21 NZ NZ227446A patent/NZ227446A/xx unknown
- 1988-12-21 CN CN88108916A patent/CN1034132A/zh active Pending
- 1988-12-21 ES ES8803876A patent/ES2011727A6/es not_active Expired - Fee Related
- 1988-12-21 NO NO88885689A patent/NO885689L/no unknown
- 1988-12-21 FR FR8816902A patent/FR2624731B1/fr not_active Expired - Fee Related
- 1988-12-21 PL PL27659588A patent/PL276595A1/xx unknown
- 1988-12-21 IE IE382088A patent/IE61995B1/en not_active IP Right Cessation
- 1988-12-21 KR KR1019880017106A patent/KR890009402A/ko not_active Application Discontinuation
- 1988-12-21 CA CA000586606A patent/CA1328078C/en not_active Expired - Fee Related
- 1988-12-21 IT IT8848702A patent/IT1224835B/it active
- 1988-12-21 SE SE8804607A patent/SE502288C2/sv not_active IP Right Cessation
- 1988-12-21 NL NL8803126A patent/NL8803126A/nl not_active Application Discontinuation
- 1988-12-22 MY MYPI88001508A patent/MY103952A/en unknown
- 1988-12-22 IL IL88764A patent/IL88764A0/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ227446A (en)	1991-08-27
SE502288C2 (sv)	1995-09-25
SE8804607D0 (sv)	1988-12-21
AT395943B (de)	1993-04-26
SE8804607L (sv)	1989-06-23
ES2011727A6 (es)	1990-02-01
FR2624731A1 (fr)	1989-06-23
GB8829793D0 (en)	1989-02-15
IL88764A0 (en)	1989-07-31
PL276595A1 (en)	1989-08-21
LU87411A1 (fr)	1989-07-07
BE1001704A3 (fr)	1990-02-13
IT1224835B (it)	1990-10-24
IE61995B1 (en)	1994-12-14
GB2211737B (en)	1991-12-11
AU2735688A (en)	1989-06-22
FR2624731B1 (fr)	1992-10-23
ZW18088A1 (en)	1989-07-26
FI885920A (fi)	1989-06-23
CA1328078C (en)	1994-03-29
IE883820L (en)	1989-06-22
PH24982A (en)	1990-12-26
DK712888D0 (da)	1988-12-21
NO885689L (no)	1989-06-23
HU204700B (en)	1992-02-28
NO885689D0 (no)	1988-12-21
PT89301A (pt)	1990-06-29
GB2211737A (en)	1989-07-12
JPH02210A (ja)	1990-01-05
KR890009402A (ko)	1989-08-01
ATA313088A (de)	1992-09-15
MY103952A (en)	1993-10-30
AU615245B2 (en)	1991-09-26
CH676665A5 (sv)	1991-02-28
DK712888A (da)	1989-06-23
PT89301B (pt)	1995-07-03
HUT50040A (en)	1989-12-28
GR880100854A (el)	1994-03-31
IT8848702A0 (it)	1988-12-21
DE3843059A1 (de)	1989-07-13
NL8803126A (nl)	1989-07-17

Publication	Publication Date	Title
CN1102388C (zh)	2003-03-05	用羟基咔唑化合物抑制平滑肌的移行与增生
CN100516062C (zh)	2009-07-22	新药物
EP0317281B1 (en)	1992-12-30	Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
CN1201812C (zh)	2005-05-18	包含环肽和化学治疗剂或血管生成抑制剂的药用制剂
KR100851679B1 (ko)	2008-08-13	2-(4-이소부틸페닐)프로피온산의 약학 조성물
EP1535916B1 (en)	2010-12-01	Inclusion complexes of butylphthalide with cyclodextrin derivatives and processes for their preparation
EP0292050B1 (en)	1991-11-21	Improved flunarizine-containing compositions
CN1152878C (zh)	2004-06-09	噻唑烷二酮衍生物及其作为抗糖尿病药的用途
RU2468015C2 (ru)	2012-11-27	Полиморфные формы деферасирокса (icl670a)
CN101357922B (zh)	2011-05-18	新的dpp-iv抑制剂
CN1034132A (zh)	1989-07-26	含哌啶基环戊基庚烯酸衍生物的水溶液配方
CN111718299B (zh)	2023-03-10	一种左西孟旦钠晶型b及其制备方法
CN1128999A (zh)	1996-08-14	杂环化合物
CN1296406A (zh)	2001-05-23	药物组合物
CN101397300B (zh)	2011-04-27	二肽酶-ⅳ抑制剂衍生物
CN105106112A (zh)	2015-12-02	一种降压药乌拉地尔组合物水针剂
CN1309649A (zh)	2001-08-22	含有多羟基烷基吡嗪衍生物的药物,新的多羟基烷基吡嗪衍生物以及它们的制备
WO2003099288A1 (fr)	2003-12-04	Composition medicinale
CN1017151B (zh)	1992-06-24	萘并硫杂氮衍生物的制备方法
JP2004051594A (ja)	2004-02-19	血管新生抑制剤
EP0449722B1 (fr)	1994-10-19	Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés
RU2428175C2 (ru)	2011-09-10	Способ получения парентерального фармацевтического раствора
AU666859B2 (en)	1996-02-29	Novel compositions based on taxane class derivatives
CN115554289A (zh)	2023-01-03	一种含丁苯酞的药物活性组合物及其制备方法
CN113105391A (zh)	2021-07-13	一种具有镇痛活性的高乌甲素衍生物及其制备方法和应用

Legal Events

Date	Code	Title
1989-07-26	C06	Publication
1989-07-26	PB01	Publication
1991-03-06	C10	Entry into substantive examination
1991-03-06	SE01	Entry into force of request for substantive examination
1998-05-20	C01	Deemed withdrawal of patent application (patent law 1993)
1998-05-20	WD01	Invention patent application deemed withdrawn after publication